

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.

Date of Report: February 2, 2009
(Date of earliest event reported)

Oragenics, Inc

(Exact name of registrant as specified in its charter)

FL
(State or other jurisdiction
of incorporation)

001-38122
(Commission File Number)

59-3410522
(IRS Employer
Identification Number)

13700 Progress Blvd
(Address of principal executive offices)

32615
(Zip Code)

386-418-4018
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 8.01 OTHER EVENTS

Orogenics, Inc. (OTCBB: ORNI) announced on February 4, 2009, that the Company has entered into an agreement with Garden of Life which provides Garden of Life with the exclusive rights to use ProBiora3 in the natural products market.

A copy of the press release announcing the agreement is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Item 9.01 FINANCIAL INFORMATION AND EXHIBITS

Exhibits.

<u>Number</u>	<u>Description</u>
99.1	Press Release dated February 4, 2009

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 4th day of February, 2009.

ORAGENICS, INC.

By: /s/ David B. Hirsch

David B. Hirsch
Chief Financial Officer

FOR IMMEDIATE RELEASE

February 4, 2009

MEDIA CONTACT

Linda Loren, Marketing Director, Oragenics, Inc.
727-456-0029 ▪ lloren@onibiopharma.com

**Oragenics, Inc., Announces Agreement
with Garden of Life, Inc., for Use of ProBiora3**

*This groundbreaking oral care probiotic ingredient will be used
in Garden of Life products*

(Alachua, FL) The Florida-based biotechnology firm Oragenics, Inc. (OTCBB: ORNI) announces that Garden of Life has been awarded rights to use its revolutionary oral-care probiotic ingredient, ProBiora3. This agreement gives Garden of Life (www.gardenoflife.com) exclusive rights to use ProBiora3 in the natural products market. ProBiora3 is a patent-pending probiotic formula containing a blend of three bacteria that work below the gum line to address oral health at its root cause.

Garden of Life is a leader in whole food nutrition, probiotics and digestive-related products, distributing more than 65 dietary supplements. Garden of Life products are sold at such retailers as Vitamin Shoppe and Whole Foods, and over 4,000 independent health food stores nationwide and overseas. The company is regarded as an industry leader, consistently ranked among the top performing companies in growth and sales by SPINS, a market research and consulting firm for the natural products industry.

“Garden of Life is a leading innovator in the natural products industry,” said Stanley Stein, Oragenics’ CEO and president. “We selected this formidable company for this exclusive relationship because we share a similar vision. Like Garden of Life, Oragenics is passionate about helping people transform their lives and attain extraordinary health through natural, biotechnological solutions. This is a terrific opportunity to have an enormous impact on oral health and wellness worldwide.”

Garden of Life President Brian Ray said the company is dedicated to “providing the most effective nutritional products in the world” for its customers. “This agreement reaffirms our longstanding commitment to combine the best of nature and science,” said Ray. “ProBiora3 is the result of many years of research and development. This type of breakthrough technology is an example of what keeps Garden of Life products at the top of our industry.”

ProBiora3 is a 100-percent natural ingredient that helps to re-establish a healthy balance of oral microflora. It’s the first complete oral care probiotic blend that supports tooth and gum health, naturally freshens breath and gently whitens teeth.

ProBiora3 was developed by Dr. Jeffrey Hillman, D.M.D., Ph.D., and chief scientific officer at Oragenics. It’s the result of more than 25 years of research, which began at the Harvard-affiliated Forsyth Institute in Boston and continued at the University of Florida. The technology has only recently become available for the general public.

For more information about ProBiora3, visit www.probiora3.com. For more information about Oragenics, Inc., visit www.oragenics.com.

To schedule an interview with Stanley Stein, contact Linda Loren at 727-456-0029; lloren@onibiopharma.com.

About Oragenics, Inc.

Oragenics, Inc., is a biopharmaceutical company engaged in developing unique proprietary technologies, some of which are being commercialized and sold in the over-the-counter consumer healthcare market. The company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, diagnostics, and oral health. The company is located in Progress Corporate Park at 13700 Progress Boulevard in Alachua, Florida, approximately 15 miles from the campus of the University of Florida in Gainesville.
